The purpose of this study is to assess efficacy and safety of patients who receive Adebrelimab combined with chemotherapy±chest radiotherapy as first-line treatment of extensive stage small cell lung cancer in the real world.

Inclusion Criteria:

1. Age:≥18 years old;
2. Patients with extensive stage small cell lung cancer confirmed by histopathology;
3. Normal function of major organs;
4. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up.

Exclusion Criteria:

1. Patients with drug allergy sufferers;
2. Serious and uncontrolled organic lesions or infections, such as decompensated heart, lung, kidney failure, etc;
3. History of psychiatric drugs abuse and can't quit or patients with mental disorders;
4. The researchers think inappropriate.

extensive stage small cell lung cancer